Jobs Simply

Vitae Pharmaceuticals News

Curis reports net loss of $2.1 million for second-quarter 2010Tuesday, August 3, 2010 @ 7:52AMCuris, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

Vitae Pharmaceuticals Receives $14 Million Milestone Payment As Boehringer Ingelheim Advances Lead Compound Into Phase ...Thursday, July 1, 2010 @ 11:17AMVitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance ...

Vitae earns $14M milestone payment from Boehringer IngelheimTuesday, June 29, 2010 @ 7:24AMVitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance ...

Vitae Pharmaceuticals Receives $14 Million Milestone Payment as Boehringer Ingelheim Advances Lead Compound into Phase ...Tuesday, June 29, 2010 @ 6:30AMFORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies.

Vitae receives $14M in diabetes projectTuesday, June 29, 2010 @ 5:02AMVitae Pharmaceuticals Inc., Fort Washington, said today that it received a $14 million "milestone" payment from its partner in developing a treatment for diabetes and other metabolic diseases.

BioLeap Appoints Dr. Gene Cordes to Its Board of DirectorsMonday, May 3, 2010 @ 11:33AMEWING, N.J. -- BioLeap, Inc., a drug design company that leverages its proprietary technology platfo...

BioLeap, Inc. Announces the Addition of Dr. Gene Cordes to Its Board of DirectorsMonday, May 3, 2010 @ 7:15AMEWING, N.J.----BioLeap, Inc., a drug design company that leverages its proprietary technology platform to conceive structurally-diverse, target-specific chemical entities, today announced that Dr.

Leading ladies of the LabFriday, December 18, 2009 @ 9:27PMYou can't really blame it on Albert Einstein, but Big Al's unique look - crazy hair and strong facial expressions - has somewhat shaped the image of modern mad scientists in popular culture. Think of a scientist, and many people will think of someone eccentric and nerdy with messy hair like Einstein's, or tall, waif-ish with perfectly waxed and combed hair plus thick glasses - and all male. Of ...

Vitae Pharmaceuticals to Present at Windhover's Annual Therapeutic Area Partnerships ConferenceWednesday, November 11, 2009 @ 6:30AMFORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced the company’s novel, clinical-stage renin inhibitor, VTP-27999, has been recognized by Windhover as a “Top 10 Project to Watch” in the cardiovascular/metabolic disease category.